Over the past decade scintimammogram (SM) had been sporadically used without much success for the detection of breast cancer using various radionuclides (Table 1). Again the role of SM as a diagnostic test was in question until 1994 when Khalkhali et al described successful breast cancer imaging 99m Tc-sestamibi prone lateral SM. Since then several authors have studied the clinical usefulness of 99m Tc-sestamibi SM in the evaluation of breast cancer. It has recently became a clinically useful method for breast cancer diagnosis. 99m Tc-sestamibi or MIBI (methoxyisobutylisonitrile) which is lipophilic 1 99m Tc organometallic complex was developed as a myocardial perfusion agent. Sestamibi uptake in various tumors including breast cancer has been reported since 1987. The exact mechanism of cellular uptake of sestamibi in cancer cells is unknown. Recent data suggest that 90 % of the tracer activity is concentrated in the mitochondria. Instruments and imaging methodology of sestamibi SM are listed on table 2 and 3. The most commonly used technique of MIBI SM is the prone lateral SM described first by Khalkhali et al
To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.